Sinovac’s jab that uses inactive agents performs poorly against the more advanced mRNA vaccines from Pfizer, Moderna, and even Russia’s Sputnik V in phase three clinical trials. However, that 50% efficacy rate for Sinovac is only for mild cases. In terms of severe illness or death, it performs at almost 100% which is critical for developing countries because it lowers hospital admission rates.
Lead the Conversation on China
Subscribe Today to Get Full Access to The China-Global South Project
$19.00 / monthly
Cancel Anytime - Renews Monthly
$199.99 / yearly
Check Out Everything You'll Get With Your Subscription
The China-Global South Daily Brief delivered to your inbox at 6AM Washington time
Full access to exclusive news and analysis from editors based in the Global South
Chinese propaganda outlets are moving to frame the narrative that Chinese-made COVID-19 vaccines are better suited for developing countries compared to those made by U.S. and European organizations. “African and some Latin American ...
China is turning to Alibaba, the massive Chinese e-commerce company, to help with the logistics in the distribution of future COVID-19 vaccines to countries throughout Africa, the Middle East, and Latin America. Cainiao ...